Pattern of Immune-Mediated Toxicities in Patients With Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab

Research unveiled at the 2018 American Society of Hematology Annual Meeting demonstrated that patients with myelodysplastic syndrome receiving combination nivolumab/ipilimumab had higher rates of immune-mediated toxicities, including cardiovascular, dermatologic, and hepatic, compared with patients receiving nivolumab or ipilimumab monotherapy.

Blood (ASH Abstract)